DADC
ALDR

D.A. Davidson & Co’s Alder Biopharmaceuticals ALDR Stock Holding History

D.A. Davidson & Co’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,397
Closed -$38K – 2231
2017
Q2 		$38K Buy
3,397
+2,897
+579% +$53.6K ﹤0.01% 1626
2017
Q1 		$10K Hold
500
– – ﹤0.01% 2039
2016
Q4 		$10K Buy
+500
New +$13K ﹤0.01% 2132
2016
Q3 		– Sell
-500
Closed -$12K – 2522
2016
Q2 		$12K Hold
500
– – ﹤0.01% 1926
2016
Q1 		$12K Buy
500
+300
+150% +$6.95K ﹤0.01% 1877
2015
Q4 		$6K Sell
200
-26
-12% -$879 ﹤0.01% 2008
2015
Q3 		$7K Buy
226
+206
+1,030% +$8.76K ﹤0.01% 1958
2015
Q2 		$1K Buy
+20
New +$727 ﹤0.01% 2183

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

D.A. Davidson & Co's ALDR Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Alder Biopharmaceuticals (ALDR) in Q3 2017, closing a stake of 3,397 shares — an estimated $38K sold.

D.A. Davidson & Co first reported a position in ALDR in Q2 2015 and held it in 8 quarters. The position peaked at $38K in Q2 2017. 132 funds tracked by Wall St. Rank hold ALDR as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Alder Biopharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 3,397 Alder Biopharmaceuticals shares in Q3 2017, an estimated $38K.
  • D.A. Davidson & Co first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 8 quarters.
  • D.A. Davidson & Co's Alder Biopharmaceuticals position peaked at $38K in Q2 2017.
  • 132 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.